AOD9604

What is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone — specifically amino acids 176-191 of the GH C-terminus, with a tyrosine modification at the N-terminal end. It was developed at Monash University in Australia with the specific goal of capturing GH's fat-burning properties while eliminating its growth-promoting effects.

AOD-9604 holds TGA (Australian Therapeutic Goods Administration) approval and has undergone Phase IIb clinical trials — making it one of the most clinically advanced peptide fat-loss compounds, with an extensive safety record across thousands of subjects.

Mechanism of Action

Beta-3 Adrenergic Receptor Activation

AOD-9604 stimulates lipolysis (fat breakdown) primarily through beta-3 adrenergic receptor activation — an entirely different pathway from the GH receptor. This means AOD-9604 can produce fat oxidation without binding the GH receptor that mediates GH's growth-promoting and potentially diabetogenic effects.

Lipogenesis Inhibition

Beyond stimulating fat breakdown, AOD-9604 inhibits lipogenesis — the formation of new fat — in adipose tissue. This dual action (increased breakdown + reduced formation) creates a favorable net negative fat balance.

No IGF-1 Elevation

Critically, AOD-9604 does not meaningfully elevate IGF-1 — unlike full GH or GHRH analogues. This distinguishes its safety profile significantly for long-term research: the IGF-1-mediated tissue growth effects that require careful monitoring in GH research are largely absent with AOD-9604.

No Diabetogenic Effect

Full growth hormone is well-known to reduce insulin sensitivity ('diabetogenic effect'). AOD-9604, because it doesn't bind the GH receptor, does not produce this metabolic disruption — a meaningful safety advantage for metabolic research.

Key Research Findings

Phase IIb Clinical Trials

AOD-9604 completed Phase IIb trials with approximately 300 subjects. While the observed fat loss magnitude was modest as a monotherapy, the compound demonstrated an exceptional safety profile: no serious adverse events, no carcinogenicity signals, no genotoxicity, and no reproductive toxicity in comprehensive preclinical testing.

Visceral Fat Reduction

Research shows selective effects on visceral and subcutaneous fat depots, with some evidence suggesting preferential visceral fat reduction — the most metabolically dangerous fat depot.

Cartilage Research

An unexpected finding from AOD-9604 research is potential chondrogenic (cartilage-building) activity — now being studied independently of the compound's fat loss applications.

*For research use only. Not for human consumption.*